MoonLake Immunotherapeutics ( (MLTX) ) just unveiled an update.
On March 31, 2025, MoonLake Immunotherapeutics entered into a loan and security agreement with Hercules Capital for up to $500 million in non-dilutive financing. This agreement, which includes a $75 million initial draw, aims to support the company’s growth, including the advancement of sonelokimab and its expected launch in 2027. The financing enhances MoonLake’s financial position, allowing it to progress its clinical trials and prepare for commercial readiness without diluting shareholder equity. The company plans to provide further updates on its clinical programs and financial strategies at a Capital Markets Update on April 29, 2025.
More about MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing sonelokimab, a novel investigational Nanobody® aimed at treating inflammatory diseases such as hidradenitis suppurativa and psoriatic arthritis. The company, founded in 2021 and headquartered in Zug, Switzerland, seeks to address major unmet needs in these conditions by leveraging the unique properties of Nanobodies®.
YTD Price Performance: -28.97%
Average Trading Volume: 452,401
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.33B
For an in-depth examination of MLTX stock, go to TipRanks’ Stock Analysis page.